Studies show J&J vaccine protects against delta variant

Preliminary findings from South Africa show that the J&J shot is highly effective against preventing hospitalizations and death

According to new data from a large-scale trial study, Johnson and Johnson’s COVID-19 vaccine was found to be highly effective against the Delta variant of the virus.

The study, known as Sisonke, of nearly 500,000 South African health workers, showed the vaccine to be 71% effective at preventing hospitalizations and 96% effective at preventing death from the variant.